Daniel T. Scavilla
About Daniel T. Scavilla
Daniel T. Scavilla is an independent director of Dentsply Sirona (XRAY), appointed February 5, 2025, and serves on the Audit and Finance Committee; he is designated by the Board as an “audit committee financial expert.” He is age 60 and independent under Nasdaq rules (all directors except the CEO are independent) . Externally, he is President and CEO of Globus Medical (since April 2022), where he led the acquisition and integration of NuVasive to create the second-largest spine technology company (market cap >$12B), and previously held senior roles at Globus and spent 28 years in finance leadership at Johnson & Johnson; he holds a B.S. in Finance & Organizational Behavior (LaSalle) and an MBA in International Management (Temple) . Dentsply Sirona emphasizes strong governance (independent non-executive chair, executive sessions without management, no hedging/pledging), and had 96.7% Say‑on‑Pay support in 2024—context for pay alignment and oversight during his tenure as director .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Globus Medical | EVP, Chief Commercial Officer & President, Trauma; previously CFO | Prior to Apr 2022 | Scaled manufacturing/distribution and launched Orthopedics & Trauma; earlier CFO role provided finance/operational leadership |
| Johnson & Johnson | Finance leadership (e.g., CFO J&J Vision; CFO Advanced Sterilization Products; roles at McNeil Consumer, Centocor, Cilag Schaffhausen) | 28 years (pre‑Globus) | Helped businesses achieve leading positions (e.g., sterilization); broad global operating/finance experience |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Globus Medical, Inc. | President & CEO; Director; Nominating & Corporate Governance Committee member | Apr 2022–present | Led NuVasive acquisition; combined entity >$12B market cap |
| Impulse Dynamics (private) | Director | Nov 2021–Jul 2023 | Cardiac device company board service |
Board Governance at XRAY (service, committees, independence)
- Director since Feb 5, 2025; member, Audit & Finance Committee; designated “audit committee financial expert” .
- Board independence: all directors except the CEO are independent; Board chaired by an independent non‑executive chair, with executive sessions held without management .
- Governance practices include no hedging/pledging, director stock ownership guidelines, and regular Board/committee assessments .
- No related person transactions were noted for 2024 .
Dual-role implications: Scavilla is CEO of Globus Medical while serving as an independent director at XRAY. The Board has determined independence under Nasdaq rules, and XRAY’s policies prohibit related party transactions and hedging/pledging. He is not an XRAY executive or chair, limiting CEO/Chair concentration and direct compensation conflicts at XRAY .
Fixed Compensation (XRAY – Director)
| Component | Amount/Terms | Vesting/Timing |
|---|---|---|
| Annual cash retainer (director) | $100,000 | Paid quarterly in advance |
| Committee chair retainers (reference) | Audit Chair $25,000; Comp & Human Capital Chair $20,000; Gov/Nom Chair $15,000; S&T Chair $15,000 | Paid quarterly in advance (for chairs) |
| Non‑Executive Chair incremental retainer | $75,000 cash + $100,000 in RSUs | Standard chair program (not applicable to Scavilla) |
| Annual director equity (RSUs) | $220,000 grant value (shares = $220,000/close) | Vests at earliest of next annual meeting, one year, or mandatory retirement age; dividend equivalents accrue |
| 2024 paid to Scavilla (pre‑appointment) | $0 fees; $0 stock awards | Joined Board in 2025; no 2024 director comp |
Performance Compensation (XRAY context; not applicable to director pay)
| Plan/Metric | Weighting | 2024 Results/Notes | Payout impact |
|---|---|---|---|
| Annual Incentive Plan (AIP) – Organic net sales | 50% | Actual $3,696M vs target $3,797M (97.4% of target) | 73.4% funding for this metric |
| AIP – Adjusted EBITDA margin % | 50% | Actual 18.5% vs target 19.7% (93.9% of target) | 71.5% funding for this metric |
| Strategic modifiers (DS Core regs, U.S. Implant, U.S. DSO, foundational initiatives, IOS placements) | Up to ±20% total (±4% each) | Net 0% modifier in 2024 | Baseline funding 72.5% reduced via negative discretion to 59.6% for Mgmt Committee |
Note: Director compensation at XRAY is not performance-based; the above illustrates the company’s pay-for-performance orientation for executives and the rigor of Compensation & Human Capital Committee oversight .
Equity Ownership & Alignment (XRAY)
| Item | Status/Amount | Notes |
|---|---|---|
| Total beneficial ownership | 0 shares (as of Mar 24, 2025) | Listed as “0” with less than 1% ownership |
| Vested vs unvested (Dec 31, 2024) | 0 options; 0 RSUs | Not yet on Board in 2024 |
| Director ownership guideline | 5x annual cash retainer (within 5 years) | All directors in compliance or within grace period |
| Hedging/pledging | Prohibited | Applies to directors and officers |
Employment Terms (XRAY – Director and Plan Protections)
- Director RSUs vest at the earliest of next annual meeting, one year from grant, or reaching mandatory retirement age; dividend equivalents accrue and settle upon vesting .
- Change-in-control: If awards are not assumed/substituted, unvested awards vest at target immediately pre‑CIC; if assumed and a qualifying termination occurs within 24 months, awards vest (performance at target) .
- Clawbacks: Dodd‑Frank compliant restatement clawback and a discretionary recoupment policy for misconduct or material harm .
- No hedging or pledging permitted; strong governance/oversight framework .
Track Record, Qualifications, and Risk Signals
- Value creation/operations: As CEO of Globus Medical, led NuVasive acquisition and integration, creating the #2 spine tech company with market cap >$12B; prior roles at Globus included CFO and scaling commercial/operations; 28 years at J&J across major medtech businesses .
- Qualifications: Deep medtech leadership, international operations, finance/strategy; Board deems him an audit committee financial expert .
- Governance/Risk: No related person transactions in 2024; Board separation of Chair/CEO; executive sessions without management; clawbacks in place .
Director Compensation (2024 detail for Scavilla)
| Year | Fees Earned ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| 2024 | 0 | 0 | 0 |
Investment Implications
- Alignment: As a new independent director with audit expertise and a no‑hedge/pledge regime plus 5x ownership guidelines, incentives point toward medium‑term alignment; initial ownership is 0 but director RSUs vest within ~one year, creating near‑term equity exposure .
- Oversight quality: Audit & Finance Committee membership and audit financial expert designation strengthen financial oversight; strong governance (independent chair, executive sessions, clawbacks) reduces governance risk .
- Selling pressure: Director RSUs vest on a short cadence (earliest of next annual meeting or one year), which can create mechanical vest‑date supply; hedging/pledging prohibitions and ownership guidelines temper adverse signaling risk .
- Conflict/independence: Dual role as Globus CEO is offset by XRAY’s independence determination and related‑party safeguards; no 2024 related transactions disclosed .